Intra-operative technology improves lumpectomy procedures for many breast cancer patients
the ONA take:
A recently developed, intra-operative technology aids lumpectomy procedures by detecting microscopic amounts of cancer cells on tumor tissue.
These cancer cells are not typically visible during or after routine surgery. The MarginProbe system, manufactured and marketed by Dune Medical Devices, employs radio-frequency spectroscopy technology to detect cancer cells in the outer margins of removed tissue.
Dr. Freya Schnabel, Director of Breast Surgery at NYU Langone, led a multi-institutional retrospective study that evaluated nearly 600 patients that underwent lumpectomies for non-palpable breast malignancies. Dr. Schnabel utilized the new tool on approximately 50 patients, and the researchers concluded that the use of the MarginProbe system may as much as triple the odds of discovering additional cancer on removed tissue margins, when compared to more traditional intra-operative imaging.
In cases when cancerous cells are found in the margin tissue by the MarginProbe, the surgeon can remove additional tissue to be certain no cancer remains.
The use of this new tool could help surgeons determine that all cancer cells are excised during the initial surgery, sparing patients unnecessary additional procedures.
New intra-operative technology aids lumpectomy procedures by detecting microscopic amounts of cancer cells on tumor tissue.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|